Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 6/2017

01-06-2017 | Hepatobiliary-Pancreas

The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation: a propensity score matching analysis

Authors: Kuan-Chieh Fang, Chien-Wei Su, Yi-You Chiou, Pei-Chang Lee, Nai-Chi Chiu, Chien-An Liu, Ping-Hsien Chen, Wei-Yu Kao, Yi-Hsiang Huang, Teh-Ia Huo, Ming-Chih Hou, Han-Chieh Lin, Jaw-Ching Wu

Published in: European Radiology | Issue 6/2017

Login to get access

Abstract

Objectives

To assess the impact of clinically significant portal hypertension (CSPH) on the prognosis of patients with hepatocellular carcinoma (HCC) undergoing radiofrequency ablation (RFA).

Methods

We retrospectively enrolled 280 treatment-naïve early-stage HCC patients who had Child–Pugh grade A or B and received upper gastrointestinal endoscopy at the time of HCC diagnosis. CSPH was defined as (1) a platelet count < 100,000/mm3 associated with splenomegaly and/or (2) the presence of oesophageal/gastric varices by endoscopy. Factors determining poor overall survival and recurrence after RFA were analysed by Cox proportional hazards model and propensity score matching analysis.

Results

A total of 192 (68.6 %) patients had CSPH. The cumulative 5-year survival rates were 50.6 % and 76.7 % in patients with and without CSPH, respectively (p = 0.015). Based on multivariate analysis, age > 65 years (hazard ratio (HR) 1.740, p = 0.025), serum albumin levels ≤ 3.5 g/dL (HR 3.268, p < 0.001) and multiple tumours (HR 1.693, p = 0.046), but not CSPH, were independent risk factors associated with poor overall survival after RFA. Moreover, the overall survival rates were comparable between patients with and without CSPH after adjusting for confounding factors via propensity score matching analysis.

Conclusions

CSPH was not associated with poor outcomes after RFA.

Key points

• CSPH was common in HCC patients who underwent RFA therapy.
• CSPH was not an independent risk factor in determining poor prognosis.
• Serum albumin level was more important to determine the outcomes.
Appendix
Available only for authorised users
Literature
1.
2.
de Lope CR, Tremosini S, Forner A, Reig M, Bruix J (2012) Management of HCC. J Hepatol 56(Suppl):S75–S87CrossRefPubMed
3.
Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC (2005) Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 54:1151–1156CrossRefPubMedPubMedCentral
4.
5.
Livraghi T, Meloni F, Di Stasi M et al (2008) Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 47:82–89CrossRefPubMed
6.
Hung HH, Chiou YY, Hsia CY et al (2011) Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol 9:79–86CrossRefPubMed
7.
Shiina S, Tateishi R, Arano T et al (2012) Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 107:569–577, quiz 578 CrossRefPubMed
8.
Kao WY, Chiou YY, Hung HH et al (2012) Younger hepatocellular carcinoma patients have better prognosis after percutaneous radiofrequency ablation therapy. J Clin Gastroenterol 46:62–70CrossRefPubMed
9.
Kim YS, Lim HK, Rhim H et al (2013) Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol 58:89–97CrossRefPubMed
10.
11.
12.
de Franchis R, Baveno VIF (2015) Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 63:743–752CrossRefPubMed
13.
D'Amico G, Pasta L, Morabito A et al (2014) Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther 39:1180–1193CrossRefPubMed
14.
King LY, Canasto-Chibuque C, Johnson KB et al (2015) A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut 64:1296–1302CrossRefPubMed
15.
Fischer MA, Kartalis N, Grigoriadis A et al (2015) Perfusion computed tomography for detection of hepatocellular carcinoma in patients with liver cirrhosis. Eur Radiol 25:3123–3132CrossRefPubMed
16.
Bucci L, Garuti F, Camelli V et al (2016) Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. Aliment Pharmacol Ther 43:385–399CrossRefPubMed
17.
Llovet JM, Fuster J, Bruix J (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30:1434–1440CrossRefPubMed
18.
Bruix J, Castells A, Bosch J et al (1996) Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 111:1018–1022CrossRefPubMed
19.
Boleslawski E, Petrovai G, Truant S et al (2012) Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis. Br J Surg 99:855–863CrossRefPubMed
20.
Cucchetti A, Cescon M, Golfieri R et al (2016) Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma. J Hepatol 64:79–86CrossRefPubMed
21.
European Association For The Study Of The L, European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943CrossRef
22.
Bruix J, Reig M, Sherman M (2016) Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150:835–853CrossRefPubMed
23.
Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 35:421–430CrossRefPubMed
24.
Su CW, Chau GY, Hung HH et al (2015) Impact of steatosis on prognosis of patients with early-stage hepatocellular carcinoma after hepatic resection. Ann Surg Oncol 22:2253–2261CrossRefPubMed
25.
D'Agostino RB Jr (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265–2281CrossRefPubMed
26.
Ishizawa T, Hasegawa K, Aoki T et al (2008) Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 134:1908–1916CrossRefPubMed
27.
Roayaie S, Jibara G, Tabrizian P et al (2015) The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology 62:440–451CrossRefPubMed
28.
Santambrogio R, Kluger MD, Costa M et al (2013) Hepatic resection for hepatocellular carcinoma in patients with Child–Pugh's A cirrhosis: is clinical evidence of portal hypertension a contraindication? HPB (Oxford) 15:78–84CrossRef
29.
Berzigotti A, Reig M, Abraldes JG, Bosch J, Bruix J (2015) Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology 61:526–536CrossRefPubMed
30.
Nault JC, De Reynies A, Villanueva A et al (2013) A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology 145:176–187CrossRefPubMed
31.
Wu WC, Chiou YY, Hung HH et al (2012) Prognostic significance of computed tomography scan-derived splenic volume in hepatocellular carcinoma treated with radiofrequency ablation. J Clin Gastroenterol 46:789–795CrossRefPubMed
32.
Ding Y, Rao SX, Chen C, Li R, Zeng MS (2015) Assessing liver function in patients with HBV-related HCC: a comparison of T(1) mapping on Gd-EOB-DTPA-enhanced MR imaging with DWI. Eur Radiol 25:1392–1398CrossRefPubMed
33.
Lee DH, Lee JM, Lee JY et al (2014) Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis. Radiology 270:900–909CrossRefPubMed
34.
35.
Lee TY, Lin JT, Zeng YS, Chen YJ, Wu MS, Wu CY (2015) Association between nucleos(t)ide analogue and tumor recurrence in HBV-related hepatocellular carcinoma after radiofrequency ablation. Hepatology. doi:10.​1002/​hep.​28266
36.
Reig M, Marino Z, Perello C et al (2016) Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol. doi:10.​1016/​j.​jhep.​2016.​04.​008
37.
Marcellin P, Gane E, Buti M et al (2013) Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381:468–475CrossRefPubMed
38.
Hosaka T, Suzuki F, Kobayashi M et al (2013) Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58:98–107CrossRefPubMed
Metadata
Title
The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation: a propensity score matching analysis
Authors
Kuan-Chieh Fang
Chien-Wei Su
Yi-You Chiou
Pei-Chang Lee
Nai-Chi Chiu
Chien-An Liu
Ping-Hsien Chen
Wei-Yu Kao
Yi-Hsiang Huang
Teh-Ia Huo
Ming-Chih Hou
Han-Chieh Lin
Jaw-Ching Wu
Publication date
01-06-2017
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 6/2017
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-016-4604-z

Other articles of this Issue 6/2017

European Radiology 6/2017 Go to the issue

Gastrointestinal

Technical feasibility and tissue reaction after silicone-covered biodegradable magnesium stent insertion in the oesophagus: a primary study in vitro and in vivo

Neuro

Ultra-high-resolution C-arm flat-detector CT angiography evaluation reveals 3-fold higher association rate for sporadic intracranial cavernous malformations and developmental venous anomalies: a retrospective study in consecutive 58 patients with 60 cavernous malformations

Neuro

Interleaving cerebral CT perfusion with neck CT angiography part I. Proof of concept and accuracy of cerebral perfusion values

Head and Neck

Prospective validation of the ultrasound based TIRADS (Thyroid Imaging Reporting And Data System) classification: results in surgically resected thyroid nodules

Urogenital

ESUR recommendations for MR imaging of the sonographically indeterminate adnexal mass: an update

Oncology

Imaging of gastrointestinal melanoma metastases: Correlation with surgery and histopathology of resected specimen